The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035

  • Lowest Price Guaranteed From USD 2,499

  • Published
    November 2017

  • Pages
    369

  • View Count
    2080

Example Insights

  1. Over 70 bioprinters are currently either commercialized or under development; of these, close to 75% have been developed by industry players. Examples of commercialized 3D bioprinters by industry stakeholders include (in alphabetical order) 3D-Bioplotter® Series (EnvisionTEC), 3D Discovery™ Series (regenHU), ALPHA-BP™ 11 (SunP Biotech), Allevi 6 / BioBot 2 (Allevi / BioBots), BIO X (CELLINK), Fab@Home M4™ (Seraph Robotics) and Jetlab® 4-Larger Area (MicroFab Technologies).
  2. Overall, more than 100 players, from both industry and academia, are currently focused on the development of 3D bioprinters and 3D bioprinted products. It is worth noting that several start-ups have emerged in the past five years; recent examples (in alphabetical order) include CELLINK, Flexadyne, Precise Bio, REGEMAT 3D, and Symme 3D. A significant proportion of startups are university spin-offs, including 3Dynamic Systems (Swansea University), Allevi (University of Pennsylvania), Aspect Biosystems (University of Columbia), Oxford MEStar (Oxford University) and Poietis(University of Bordeaux).
  3. Around 60 research institutions are currently active in this field. In fact, close to 30% of the players are focused on developing their own 3D bioprinters; examples include (in alphabetical order), Clemson University, Heriot-Watt University, Ludwig Maximilian University of Munich (LMU), Medical University of South Carolina (MUSC), Nanyang Technological University (NTU), Technical University of Munich (TUM), University of Toronto, University of Wollongong and Wake Forest Baptist Medical Center.
  4. Over 60% of the available bioprinters are based on the extrusion technology; examples include (in alphabetical order) ALPHA (3Dynamic Systems), Bio3D SYN^ (Bio3D Technologies), Bioscaffolder 3.1 (GeSim), Regenovo Bio-Printer (Regenovo Biotechnology) and UN-BIO-MINI / MINI Bio-printer (Qingdao Unique Products Develop). This is followed by inkjet-based bioprinters and laser-based bioprinters, which presently represent 26% and 2% of the total number of bioprinters, respectively. Apart from these, other types of technologies used in bioprinters include Kenzan technology, synQUAD technology, piezoelectric nanoelectric pipetting and freeze-drying deposition mechanisms.
  5. Several players are actively engaged in attempts to come up with new and innovative bioprinting techniques. This activity can be observed in the increasing number of patent applications filed related to 3D bioprinting. Of the total number of patents filed / granted from 1992 to late 2017, over 85% of the patents were filed in the last five years, beginning 2013.The US and China have emerged as global leaders in terms of intellectual property; these regions currently contribute to 37% and 27% of the filed patents, respectively.
  6. The number of partnerships established annually over the past five years demonstrate an increasing trend; we identified over 65 partnerships inked during the period 2012-2017. Majority of these partnerships are focused on R&D activities related to bioprinting technologies and products. Examples of recent research agreements include collaborations between Organovo and Viscient Biosciences (November 2017), Poietis and BASF (October 2017), Aether and University of South Australia (UniSA) (August 2017), GeSim and BellaSeno (August 2017).
  7. A variety of interesting trends, such as the development of bioinks in ready to print formats (by companies such as CELLINK) and introduction of the concept of 4D bioprinting (by companies such as Poietis), are emerging. In addition, several companies, for instance, Allevi (BioBots), BioCurious, Ourobotics, Seraph Robotics and SunP Biotech International, have undertaken efforts to develop low cost bioprinters. Multiple initiatives have also been launched to modify the existing 3D bioprinting techniques and come up with scaffold-free bioprinters.
  8. As different products get approved for a diverse range of applications within the pharmaceutical / biotechnology market, we expect the market to witness a series of growth spurts across different applications, such as drug testing / drugscreening, tissue engineering / tissue implants and organ transplants, in the coming years. Overall, we expect the 3D bioprinted products market to grow at an annualized rate of over 64% between 2018 and 2035.
  9. Specifically, 3D printed organs for transplantation are expected to drive the long-term growth in this field; by 2035, we are led to believe that such organs have the potential to contribute to around 25% of the market’s share by 2035.  North America and Europe are likely to maintain their dominance over the next decade. However, emerging regions, such as China, are expected to grow at a relatively faster rate as compared to the developed regions.

Overview

3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues. For instance, in 2015, 3D Bioprinting Solutions became the first company to print and transplant a thyroid gland in a mouse. Subsequently, in the same year, Aspect Biosystems developed and commercialized 3D printed human respiratory tissue for clinical testing. In addition to these, other companies with commercialized tissue products include MEDPRIN, Poietis, and Nano3D Biosciences.

The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.

The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.

 

Scope of Report

The 3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035’ report providesa comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting. Amongst other things, the report features:

  • A detailed overview of the current market landscape of 3D bioprinters and 3D bioprinted products, highlighting the contributions of industry and non-industry players, including information on the various technological aspects and key specifications of such technologies / products.
  • Profiles of developers of bioprinting devices / technologies and bioprinted products. Each profile includes an overview of the company, information on their financials (wherever available), details on their respective product portfolios, 3D bioprinting specific collaborations, and an informed future outlook.
  • A comprehensive product competitiveness analysis of existing 3D bioprinters, based on supplier power and product specific features such as type of technology and range of applications.
  • An analysis of the partnerships that have been established in the recent past, covering research agreements, distribution agreements, product development agreements and other relevant deals, along with information on the collaborators / partners.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.
  • An analysis depicting the prevalent and emerging trends in 3D bioprinting as observed on the social media platform, Twitter. The report also includes a detailed case study on the upcoming trends, such as use of stem cells as bioinks, emergence of the concept of 4D bioprinting and commercialization of low-cost bioprinters, based on inputs from primary and secondary research.
  • An analysis of intellectual property portfolio related to 3D bioprinting. The study presents a high-level view on the granted patents and submitted patent applications related to these technologies, highlighting the prevalent trends in this domain. In addition, the analysis highlights the most active geographies and the key players driving innovation in this field.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, expected adoption rates and pricing, we have provided an informed estimate of the likely evolution of the opportunity within the market in the short to mid-term and long term, for the period 2018-2035. To account for the uncertainties associated with the development of 3D bioprinted products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Douglas Chrisey (Professor, Tulane University), Lisa Oliver (Doctor, University of Nantes) and Fanny Geraldo (Engineer, University of Nantes), Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences), Igor Zlatkin (Application Scientist, Digilab), Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt), Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices), Lauralyn McDaniel (Industry Manager, SME), Marc Thurner (Chief Executive Officer, regenHU), Roger Narayan (Professor, North Carolina State University) and Simon Fried (Chief Business Officer, Nano Dimension). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the 3D bioprinting market in the mid to long term.

Chapter 3  provides a general overview of 3D bioprinting, covering its historical background, evolution and current applications. In addition, the section provides information on the material and technical requirements, and the process of bioprinting.

Chapter 4  provides a comprehensive market landscape of 3D bioprinters and bioprinted products that have already been developed and / or are under development. This chapter includes information on the developers, applications, technologies, details on different printing parameters (for instance, cell viability, precision, print speed and resolution) and the cost of bioprinters. 

Chapter 5  presents profiles of some of the active players ( based on the number of bioprinters / commercialized  bioprinted products ) in this domain, highlighting their expertise related to 3D bioprinters and bioprinted products. Each profile provides a brief overview of the company, 3D bioprinting devices and / or bioprinted products, its financial information ( wherever available ), recent developments and a comprehensive future outlook.

Chapter 6  features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this market. The chapter includes details on the different partnership models, such as research agreements, distribution agreements, product development agreements and licensing agreements that have been established in the period between 2012 and late 2017. In addition, we have presented details on the various investments and grants received by companies between 2012 to late 2017, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 7  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of 3D bioprinting, under a comprehensive SWOT framework.

Chapter 8  provides insights on the popularity of 3D bioprinting on the social media platform, Twitter. The section features an analysis of the yearly distribution of tweets posted on the platform in the time period 2012 to late 2017, highlighting the most significant events responsible for the increase / decrease in the volume of tweets each year

Chapter 9  provides insights on recent trends in the 3D bioprinting industry, such as scaffold-free printing, stem cell basedbioinks, 4D bioprinting and advent of low-cost bioprinters, which are expected to influence the adoption of bioprintedproducts in the coming years.

Chapter 10  features a comparison of product competitiveness and supplier power of bioprinters in the form of a 2 x 2 matrix. The analysis takes into considerations several parameters such as type of technology and range of applications offered by these bioprinters.

Chapter 11  provides a detailed analysis of the patents that have been filed in the field of 3D bioprinting. The analysis highlights emerging trends in the intellectual property portfolio of this field, and identifies the key players that are driving innovation in this space.

Chapter 12  presents a comprehensive market forecast analysis, highlighting the future potential of 3D bioprinting, till the year 2035. We have segregated the opportunity on the basis of the type of application of the bioprinted product (drug testing / drug screening, tissue engineering / tissue implants and organ transplant), type of bioprinting technology (extrusion, inkjet, laser and others) and the geographical distribution of the market (North America, Europe, Asia Pacific and Rest of the World). The sales potential and future growth opportunity were estimated based on the target patient population, likely adoption rates and the likely price of products.

Chapter 13  is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14  is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of discussions held with the following individuals:

  1. Douglas Chrisey (Professor, Tulane University)
  2. Lisa Oliver (Doctor, University of Nantes) and Fanny Geraldo (Engineer, University of Nantes)
  3. Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences)
  4. Igor Zlatkin (Application Scientist, Digilab)
  5. Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt)
  6. Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices)
  7. Lauralyn McDaniel (Industry Manager, SME)
  8. Marc Thurner (Chief Executive Officer, regenHU)
  9. Roger Narayan (Professor, North Carolina State University)
  10. Simon Fried (Chief Business Officer, Nano Dimension)

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. Overview
3.2.2. Historical Evolution
3.2.3. 3D Printing in Medicine
3.3. 3D Bioprinting: Printing of Living Cells, Tissues and Organs
3.3.1. Historical Evolution
3.3.2. Process and Requirements
3.3.3. 3D Bioprinting Applications
3.3.3.1. Toxicity Screening / Drug Testing
3.3.3.2. Tissue Engineering
3.3.3.3. Organ Replacement
 
4. Market Landscape
4.1. Chapter Overview
4.2. 3D Bioprinting: Overall Market Landscape
4.2.1. 3D Bioprinters by Industry Players
4.2.1.1. Distribution by Geographical Location of Developers
4.2.1.2. Distribution by Founding Year of Developers
4.2.1.3. Distribution by Applications
4.2.1.4. Distribution by Cost of 3D bioprinters
4.2.1.5. Distribution by Technology of 3D bioprinters
4.2.1.6. Physical Features of 3D Bioprinters
4.2.1.7. Printing Parameters of 3D Bioprinters
4.2.2. 3D Bioprinted Products by Industry Players
4.2.2.1. Distribution by Geographical Location of Developers
4.2.2.2. Distribution by Type of Product
 
4.2.3. 3D Bioprinters by Non-Industry Players
4.2.3.1. Distribution by Geographical Location of Developers
4.2.3.2. Distribution by Development Status
 
4.2.4. 3D Bioprinted Products by Non-Industry Players
4.2.4.1. Distribution by Geographical Location of Developer
4.2.4.2. Distribution by Type of Product
4.2.4.3. Distribution by Development Status
 
5. Company Profiles
5.1. Chapter Overview
5.2. 3Dynamic Systems
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.2.1. 3DS Alpha
5.2.2.1.1. Key Features
5.2.2.2. 3DS Omega
5.2.2.2.1. Key Features
5.2.2.3. Gel4Cell®
5.2.2.3.1. Key Features
5.2.3. Recent Developments
5.2.4. Future Outlook
 
5.3. Aspect Biosystems
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.2.1. Lab-on-a-Printer™  Technology
5.3.2.2. 3DAirwayALI™ 
5.3.2.3. 3DBioRing™  Airway
5.3.2.4. RX1™ 
5.3.2.4.1. Key Features
5.3.2.4.2. Applications
5.3.3. Awards and Accomplishments
5.3.4. Recent Developments
5.3.4.1. Investments and Expansions
5.3.4.2. Partnerships and Collaborations
5.3.5. Future Outlook
 
5.4. Allevi (formerly BioBots)
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.2.1. Allevi 2
5.4.2.2. Key Features
5.4.2.2.1. Applications
5.4.2.3. Allevi 6
5.4.2.3.1. Key Features
5.4.2.3.2. Applications
5.4.3. Awards and Accomplishments
5.4.4. Future Outlook
 
5.5. BioDan Group
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.2.1. Bioprinted Skin
5.5.3. Recent Developments
5.5.4. Future Outlook
 
5.6. CELLINK
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.2.1. INKREDIBLE
5.6.2.1.1. Key Features
5.6.2.2. INKREDIBLE+
5.6.2.2.1. Key Features
5.6.2.3. BIO X
5.6.2.3.1. Key Features
5.6.2.3.2. Applications
5.6.2.4. Bioinks
5.6.3. Awards and Accomplishments
5.6.4. Recent Developments
5.6.4.1. Investments and Expansions
5.6.4.2. Partnerships and Collaborations
5.6.5. Future Outlook
 
5.7. EnvisionTEC
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.2.1. 3D-Bioplotter® Starter Series
5.7.2.1.1. Key Features
5.7.2.2. 3D-Bioplotter® Developer Series
5.7.2.2.1. Key Features
5.7.2.3. 3D-Bioplotter® Manufacturer Series
5.7.2.3.1. Key Features
5.7.2.4. Applications
5.7.3. Awards and Accomplishments
5.7.4. Recent Developments
5.7.4.1. Partnerships and Collaborations
5.7.5. Future Outlook
 
5.8. GeSiM
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.2.1. BioScafolder 3.1
5.8.2.1.1. Key Features
5.8.2.1.2. Applications
5.8.3. Recent Developments
5.8.3.1. Partnerships and Collaborations
5.8.4. Future Outlook
 
5.9. MEDPRIN BIOTECH
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.2.1. ReDura® Biomimetic-Synthetic-Absorbable Dural Substitute
5.9.2.1.1. Development of ReDura®
5.9.2.1.2. Key Features
5.9.2.2. NeoDura™
5.9.2.2.1. Key Features
5.9.3. Recent Developments
5.9.4. Future Outlook
 
5.10. microdrop Technologies
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.2.1. Autodrop Compact System
5.10.2.1.1. Key Features
5.10.2.2. Autodrop Professional Positioning System AD-P-8000
5.10.2.2.1. Key Features
5.10.2.3. Applications
5.10.3. Recent Developments
5.10.4. Future Outlook
 
5.11. MicroFab Technologies
5.11.1. Company Overview
5.11.2. Product Portfolio
5.11.2.1. jetlab® 4 Printing Platforms
5.11.2.1.1. Key Features
5.11.2.1.2. Applications
5.11.2.2. jetlab II-Precision
5.11.2.2.1. Key Features
5.11.2.2.2. Applications
5.11.3. Recent Developments
5.11.3.1. Partnerships and Collaborations
5.11.4. Future Outlook
 
5.12. Nano3D Biosciences
5.12.1. Company Overview
5.12.2. Product Portfolio
5.12.3. Magnetic 3D Bioprinting
5.12.3.1. Key Features
5.12.3.2. Applications
5.12.4. Recent Developments
5.12.5. Partnerships and Collaborations
5.12.6. Future Outlook
 
5.13. Organovo
5.13.1. Company Overview
5.13.2. Financial Performance
5.13.3. Product Portfolio
5.13.3.1. NovoGen MMX™
5.13.3.1.1. Development of NovoGen MMX™
5.13.3.1.2. The Bioprinting Process
5.13.3.1.3. Bioink
5.13.3.1.4. Key Features
5.13.3.1.5. Applications
5.13.3.2. ExVive™ 3D Bioprinted Human Liver Tissues
5.13.3.3. ExVive™ 3D Bioprinted Kidney Tissues
5.13.3.3.1. Applications of Human ExVive™ 3D Models
5.13.3.4. Key Preclinical Results of Bioprinted Tissues
5.13.4. Awards and Accomplishments
5.13.5. Recent Developments
5.13.5.1. Investments and Expansions
5.13.5.2. Partnerships and Collaborations
5.13.6. Future Outlook
 
5.14. Qingdao Unique Products Develop
5.14.1. Company Overview
5.14.2. Product Portfolio
5.14.2.1. 3D Bio-Printer
5.14.2.2. Anyprint B01CS
5.14.2.3. Bio-Membrane Printer
5.14.2.4. MINI Bio Printer
5.14.2.5. Re-human
5.14.3. Future Outlook
 
5.15. regenHU
5.15.1. Company Overview
5.15.2. Product Portfolio
5.15.2.1. 3DDiscovery™
5.15.2.1.1. Key Features
5.15.2.1.2. Applications
5.15.2.2. BioFactory™
5.15.2.2.1. Key Features
5.15.2.2.2. Applications
5.15.3. Bioinks
5.15.3.1. Key Features
5.15.3.2. OsteoInk™
5.15.3.2.1. Key Features
5.15.3.3. STARK™
5.15.3.3.1. Key Features
5.15.4. Recent Developments
5.15.4.1. Partnerships and Collaborations
5.15.5. Future Outlook
 
5.16. SunP Biotech International
5.16.1. Company Overview
5.16.2. Product Portfolio
5.16.2.1. ALPHA-BP™ 11
5.16.2.1.1. Key Features
5.16.2.2. ALPHA-CPD1
 
5.16.2.2.1. Key Features
5.16.2.3. APLHA-CPT1
5.16.2.3.1. Key Features
5.16.3. Future Outlook
 
6. Recent Collaborations and Funding
6.1. Chapter Overview
6.2. Partnership Models
6.3. 3D Bioprinting: Recent Collaborations
6.3.1. Analysis by Year of Collaborations
6.3.2. Analysis by Type of Collaboration
6.3.3. 3D Bioprinting Collaborations: Most Active Players
6.4. Types of Funding
6.5. 3D Bioprinting: Funding Instances
6.5.1. Analysis by Type of Funding Instance
6.6. Most Active Companies: Analysis by Number of Funding Instances
 
7. SWOT Analysis
7.1. Chapter Overview
7.2. Strengths
7.2.1. Automating the Discovery / Development of Regenerative Medicine
7.2.2. Quality Alternative to Animal Testing
7.2.3. Expediting Drug Development and Reducing R&D Expenditure
7.2.4. Support from Government and Research Institutions
7.2.5. Innovations in Biomaterials to Complement Growth
7.3. Weaknesses
7.3.1. High Initial Investments
7.3.2. Issues Related to Replicating 3D Structures
7.3.3. Concerns Associated with Low Cell Viability
7.3.4. Scarcity of Alternatives to Traditional 3D Printing Methods
7.4. Opportunities
7.4.1. Customizing Organs for Transplantation
7.4.2. Less Entry Barriers in Emerging regions
7.4.3. Advent of in-situ Bioprinting Techniques
7.5. Threats
7.5.1. Regulatory Challenges
7.5.2. Ethical Concerns
7.5.3. Competition from Existing 3D Culture Systems
 
8. Emerging Trends on Social Media
8.1. Chapter Overview
8.2. Trends on Twitter
8.3. Popular Keywords and Word Cloud Analysis
 
9. Recent Trends in 3D Bioprinting Industry
9.1. Chapter Overview
9.2. Introduction of Scaffold-Free Bioprinting
9.3. Emergence of 4D Bioprinting: The Next Generation of Bioprinting
9.4. Use of Stem Cells as Bio Ink
9.5. Development of UV 3D Bioprinting, a Modified Stereolithography Approach
9.6. Introduction of Novel Bioprinting Technologies
9.7. Establishment of Academic Spin-Offs
9.8. Entry of Well-Established Players of 3D Printing Industry in Bioprinting Industry
9.9. Introduction of Low-Priced Bioprinters
9.10. Increasing Number of Initiatives Taken by Governments of Different Countries
 
10. Product Competitiveness Analysis
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. 3D Bioprinters: 2x2 Product Competitiveness vs. Supplier Power Analysis
 
11. Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. 3D Bioprinting Patents: Distribution by Publication Year
11.4. 3D Bioprinting Patents: Distribution by Geographical Location
11.5. 3D Bioprinting Patents: Distribution by CPC Classifications
11.6. 3D Bioprinting Patents: Emerging Areas
11.7. 3D Bioprinting Patents: Leading Players
 
12. Market Forecast and Opportunity Analysis
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall 3D Bioprinting Market, 2018-2035
12.4. 3D Bioprinting Market: Distribution by Applications
12.4.1. 3D Bioprinting Market for Drug Testing / Drug Screening
12.4.2. 3D Bioprinting Market for Tissue Engineering / Tissue Implants
12.4.2.1. 3D Bioprinted Skin
12.4.2.2. 3D Bioprinted Cornea
12.4.2.3. 3D Bioprinted Cartilage
12.4.2.4. 3D Bioprinted Bone
12.4.2.5. 3D Bioprinted Blood Vessels
12.4.2.6. 3D Bioprinted Heart Valve
 
12.4.3. 3D Bioprinting Market for Organ Transplants
12.4.3.1. 3D Bioprinted Breast Implants
12.4.3.2. 3D Bioprinted Kidneys
12.4.3.3. 3D Bioprinted Liver
12.4.3.4. 3D Bioprinted Heart
 
12.5. 3D Bioprinting Market: Distribution by Region (North America, Europe, Asia Pacific and Rest of the World)
12.6. 3D Bioprinting Market: Distribution by Technology (Extrusion, Inkjet, Laser and Others)
 
13. Conclusion
13.1. 3D Bioprinting has Garnered Significant Attention within the Healthcare Industry
13.2. The Competitive Market Landscape Features a Mix of Industry and Non-industry Players
13.3. North America and Europe Dominate the Current Market; Several Companies based in Asia Pacific are also Making Notable Progress
13.4. Research Continues to be the Major Focus as Stakeholders Strive to Improve Existing Methods and Technologies
13.5. Increasing Partnership Activity and Financial Support from Public and Private Investors are Expected to Drive Growth
13.6. Recent Advances are Expected to Act as Catalyst to the Success of 3D Bioprinting
13.7. Inherent Challenges Must be Overcome to Tap the Multi-billion Dollar Opportunity in the Long Term
 
14. Interview Transcripts
14.1. Chapter Overview
14.2. Douglas Chrisey, Professor, Tulane University
14.3. Igor Zlatkin, Application Scientist and Chirantan Kanani, Technology & Product Development, Digilab
14.4. Lisa Oliver (Doctor, University of Nantes) and Fanny Geraldo (Engineer, University of Nantes)
14.5. Glauco R Souza, President & Chief Scientific Officer and Hubert Tseng, Senior Research Scientist, n3D Biosciences
14.6. Kenneth Church, President & Chief Executive Officer and Xudong Chen, Executive Vice President Business Development & Sales, nScrypt
14.7. Laura Bosworth, Chief Executive Officer & Co-Founder, TeVido BioDevices
14.8. Lauralyn McDaniel, Industrial Manager, SME
14.9. Marc Thurner, Chief Executive Officer, regenHU
14.10. Roger Narayan, Professor, North Carolina State University
14.11. Simon Fried, Chief Business Officer, Nano Dimension
14.12. Anonymous, MicroFab Technologies
 
15. Appendix 1: Tabulated Data
 
16. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1  The Bioprinting Process
Figure 4.1  3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
Figure 4.2  3D Bioprinters by Industry Players: Cumulative Distribution by Founding Year of Developers
Figure 4.3  3D Bioprinters by Industry Players: Distribution by Applications
Figure 4.4  3D Bioprinters by Industry Players: Distribution by Cost (USD)
Figure 4.5  3D Bioprinters by Industry Players: Distribution by Technology
Figure 4.6  3D Bioprinters by Industry Players: Distribution by Printer Weight 
Figure 4.7  3D Bioprinters by Industry Players: Distribution by Number of Printheads
Figure 4.8  3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
Figure 4.9  3D Bioprinted Products by Industry Players: Distribution by Product Type
Figure 4.10  3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Developers
Figure 4.11  3D Bioprinters by Non-Industry Players: Distribution by Development Status
Figure 4.12  3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Developers
Figure 4.13  3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
Figure 4.14  3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
Figure 5.1 Organovo: Revenues, FY2013- Q1 FY2018 (USD Million)
Figure 6.1 3D Bioprinting Collaborations: Cumulative Distribution by Year, 2012-2017
Figure 6.2 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
Figure 6.3  3D Bioprinting Collaborations: Most Active Players, 2012-2017
Figure 6.4  3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
Figure 6.5  3D Bioprinting Funding Instances: Most Active Players, 2012-2017
Figure 7.1  3D Bioprinting Market: SWOT Analysis
Figure 7.2  3D Bioprinting SWOT Analysis: Strengths
Figure 7.3  3D Bioprinting SWOT Analysis: Weaknesses
Figure 7.4  3D Bioprinting SWOT Analysis: Opportunities
Figure 7.5  3D Bioprinting SWOT Analysis: Threat
Figure 8.1  3D Bioprinting Social Media Analysis: Yearly Distribution of Tweets, January 2012-September 2017
Figure 8.2  3D Bioprinting Social Media Analysis: Popular Keywords on Twitter, January 2012 to September 2017
Figure 10.1  3D Bioprinters: Product Competitiveness Analysis
Figure 11.1  3D Bioprinting Patents: Distribution by Publication Type
Figure 11.2  3D Bioprinting Patents: Cumulative Distribution by Publication Year
Figure 11.3  3D Bioprinting Patents: Distribution by Year and Regions
Figure 11.4  3D Bioprinting Patents: Distribution by CPC Classification Symbol
Figure 11.5  3D Bioprinting Patents: Emerging Areas
Figure 11.6  3D Bioprinting Patents: Leading Assignees
Figure 11.7  3D Bioprinting Patents: Geographical Distribution of Leading Assignees
Figure 12.1  3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.2  3D Bioprinting Market: Long-Term (2027-2035), Base Scenario (USD Billion)
Figure 12.3  3D Bioprinting Market: Distribution by Applications 2020, 2030 and 2035, Base Scenario
Figure 12.4  3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.5  3D Bioprinting Market for Drug Testing / Drug Screening: Long-Term (2027-2035), Base Scenario (USD Billion)
Figure 12.6  3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.7  3D Bioprinting Market for Tissue Engineering / Tissue Implants: Long-Term (2027-2035), Base Scenario (USD Billion)
Figure 12.8  3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario 
Figure 12.9  3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Figure 12.10 3D Bioprinting Market for Bioprinted Skin: Long-Term, (Till 2035), Base Scenario (USD Billion)
Figure 12.11  3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.12  3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.13  3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.14  3D Bioprinting Market for Bioprinted Blood Vessels: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.15  3D Bioprinting Market for Bioprinted Heart Valves: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.16  3D Bioprinting Market for Organ Transplants: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.17  3D Bioprinting Market for Bioprinted Breast Implants: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.18 3D Bioprinting Market for Bioprinted Kidney: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.19 3D Bioprinting Market for Bioprinted Liver: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.20  3D Bioprinting Market for Bioprinted Heart: Long-Term (Till 2035), Base Scenario (USD Billion)
Figure 12.21  3D Bioprinting Market: Distribution by Region, (2018, 2027 and 2035), (Base Scenario) 
Figure 12.22  3D Bioprinting Market: Distribution by Technology, (2018, 2027 and 2035), (Base Scenario) 
Figure 13.1  3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)

List of Tables

Table 3.1  Inputs for 3D Bioprinting
Table 4.1  List of 3D Bioprinters by Industry Players
Table 4.2  3D Bioprinters by Industry Players: Bioprinting Technologies
Table 4.3  3D Bioprinters by Industry Players: Physical Features
Table 4.4 3D Bioprinters by Industry Players: Printing Parameters
Table 4.5 List of 3D Bioprinted Products by Industry Players
Table 4.6  List of 3D Bioprinters by Non-Industry Players
Table 4.7  List of 3D Bioprinted Products by Non-Industry Players
Table 5.1  3Dynamic Systems: Product Portfolio
Table 5.2 3Dynamic Systems: Technical Specifications of 3DS Alpha
Table 5.3  3Dynamic Systems: Technical Specifications of 3DS Omega
Table 5.4  Aspect Biosystems: Product Portfolio 
Table 5.5  Aspect Biosystems: Technical Specifications of RX1™
Table 5.6 Allevi (BioBots): Product Portfolio
Table 5.7 Allevi (BioBots): Technical Specifications of Allevi 2
Table 5.8  Allevi (BioBots):  Technical Specifications of Allevi 6
Table 5.9  BioDan Group: Product Portfolio 
Table 5.10  CELLINK: Product Portfolio
Table 5.11  CELLINK: Technical Specifications of INKREDIBLE 
Table 5.12  CELLINK: Technical Specifications of INKREDIBLE+ 
Table 5.13  CELLINK: Technical Specifications of BIO X
Table 5.14  CELLINK: Specifications of Bioinks
Table 5.15  EnvisionTEC: Product Portfolio
Table 5.16 EnvisionTEC: Consumables for 3D-Bioplotter® Bioprinters
Table 5.17 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Starter Series
Table 5.18 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Developer Series
Table 5.19 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Manufacturer Series
Table 5.20 GeSiM: Product Portfolio
Table 5.21 GeSiM: Technical Specifications of BioScaffolder3.1
Table 5.22 MEDPRIN BIOTECH: Product Portfolio
Table 5.23 MEDPRIN BIOTECH: Technical Specifications of ReDura™
Table 5.24 microdrop Technologies: Product Portfolio
Table 5.25 microdrop Technologies: Technical Specifications of Autodrop Compact System
Table 5.26  microdrop Technologies: Technical Specifications of Autodrop Professional Positioning System AD-P-8000
Table 5.27  MicroFab Technologies: Product Portfolio
Table 5.28 MicroFab Technologies: Technical Specifications of jetlab®4
Table 5.29  MicroFab Technologies: Technical Specifications of jetlab® II-Precision
Table 5.30 n3D Biosciences: Product Portfolio
Table 5.31 Organovo: Product Portfolio 
Table 5.32 Qingdao Unique Products Develop: Product Portfolio
Table 5.33 Qingdao Unique Products Develop: Technical Specifications of 3D Bio-Printer
Table 5.34 Qingdao Unique Products Develop: Technical Specifications of Anyprint B01CS
Table 5.35 Qingdao Unique Products Develop: Technical Specifications of Bio-Membrane Printer
Table 5.36 Qingdao Unique Products Develop: Technical Specifications of MINI Bio-Printer
Table 5.37 regenHU: Product Portfolio
Table 5.38 regenHU: Technical Specifications of 3DDiscovery™
Table 5.39 regenHU: Technical Specifications of BioFactory™
Table 5.40 regenHU: Types and Details of ECM-BioInks™
Table 5.41 regenHU: Technical Specifications of OsteoInk™
Table 5.42 SunP Biotech International: Product Portfolio
Table 5.43 SunP Biotech: Technical Specifications of APLHA-BP™ 11
Table 5.44 SunP Biotech International: Technical Specifications of ALPHA-CPD1
Table 5.45 SunP Biotech International: Technical Specifications of APLHA-CPT1
Table 6.1 3D Bioprinting: Recent Collaborations, 2012-2017
Table 6.2 3D Bioprinting: List of Funding Instances and Investors, 2012-2017 
Table 6.3 3D Bioprinting: Types of Funding Instances, 2012-2017
Table 11.1 3D Bioprinting Patents: CPC Symbol Definitions
Table 11.2 3D Bioprinting Patents: Most Popular CPC Symbols 
Table 11.3 3D Bioprinting Patents: List of Top CPC Classifications
Table 12.1 Expected Launch Timeline of 3D Bioprinted Products for Different Applications 
Table 15.1 3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
Table 15.2  3D Bioprinters by Industry Players: Cumulative Distribution by Founding Year of Developers
Table 15.3 3D Bioprinters by Industry Players: Distribution by Applications
Table 15.4  3D Bioprinters by Industry Players: Distribution by Cost (USD)
Table 15.5 3D Bioprinters by Industry Players: Distribution by Technology
Table 15.6 3D Bioprinters by Industry Players: Distribution by Printer Weight 
Table 15.7 3D Bioprinters by Industry Players: Distribution by Number of Printheads
Table 15.8 3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
Table 15.9  3D Bioprinted Products by Industry Players: Distribution by Product Type
Table 15.10 3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Academia
Table 15.11  3D Bioprinters by Non-Industry Players: Distribution by Development Status
Table 15.12  3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Academia
Table 15.13  3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
Table 15.14  3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
Table 15.15 Organovo: Annual Revenues, 2011- 2017 (USD Million)
Table 15.16 3D Bioprinting Collaborations: Distribution by Year, 2012-2017
Table 15.17 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
Table 15.18 3D Bioprinting Collaborations: Most Active Players, 2012-2017
Table 15.19 3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
Table 15.20 3D Bioprinting Funding Instances: Distribution by Total Amount Invested, 2012-2017 (USD Million)
Table 15.21 3D Bioprinting Funding Instances: Most Active Players, 2012-2017
Table 15.22 3D Bioprinting Patents: Distribution by Publication Type
Table 15.23 3D Bioprinting Patents: Distribution by Publication Year
Table 15.24 3D Bioprinting Patents: Distribution by Year and Regions
Table 15.25 3D Bioprinting Patents: Leading Assignees
Table 15.26 3D Bioprinting Patents: Geographical Distribution of Leading Assignees
Table 15.27 3D Bioprinting Market: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
Table 15.28 3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Table 15.29 3D Bioprinting Market: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
Table 15.30 3D Bioprinting Market: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.31 3D Bioprinting Market: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.32 3D Bioprinting Market: Distribution by Applications 2020, 2030 and 2035., Conservative Scenario (USD Billion)
Table 15.33 3D Bioprinting Market: Distribution by Applications, 2020, 2030 and 2035, Base Scenario (USD Billion)
Table 15.34 3D Bioprinting Market: Distribution by Applications 2020, 2030 and 2035, Optimistic Scenario (USD Billion)
Table 15.35  3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
Table 15.36 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Table 15.37  3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
Table 15.38 3D Bioprinting Market for Drug Testing / Drug Screening: Long-Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.39 3D Bioprinting Market for Drug Testing / Drug Screening: Long-Term (2027-2035), Base Scenario (USD Billion)
Table 15.40 3D Bioprinting Market for Drug Testing / Drug Screening: Long-Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.41 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
Table 15.42 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Table 15.43 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
Table 15.44 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Long-Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.45 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Long-Term (2027-2035), Base Scenario (USD Billion)
Table 15.46 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Long-Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.47 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Conservative Scenario (USD Billion)
Table 15.48 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario (USD Billion)
Table 15.49 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Optimistic Scenario (USD Billion)
Table 15.50 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
Table 15.51 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Table 15.52 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
Table 15.53 3D Bioprinting Market for Bioprinted Skin: Long-Term, (2027-2035), Conservative Scenario (USD Billion)
Table 15.54 3D Bioprinting Market for Bioprinted Skin: Long-Term, (2027-2035), Base Scenario (USD Billion)
Table 15.55 3D Bioprinting Market for Bioprinted Skin: Long-Term, (2027-2035), Optimistic Scenario (USD Billion)
Table 15.56 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.57  3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.58 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.59 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.60  3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.61 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.62 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.63  3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.64 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.65 3D Bioprinting Market for Bioprinted Blood Vessels: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.66  3D Bioprinting Market for Bioprinted Blood Vessels: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.67 3D Bioprinting Market for Bioprinted Blood Vessels: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.68 3D Bioprinting Market for Bioprinted Heart Valves: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.69  3D Bioprinting Market for Bioprinted Heart Valves: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.70 3D Bioprinting Market for Bioprinted Heart Valves: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.71 3D Bioprinting Market for Organ Transplants: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.72  3D Bioprinting Market for Organ Transplants: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.73 3D Bioprinting Market for Organ Transplants: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.74 3D Bioprinting Market for Bioprinted Breast Implants: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.75  3D Bioprinting Market for Bioprinted Breast Implants: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.76 3D Bioprinting Market for Bioprinted Breast Implants: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.77 3D Bioprinting Market for Bioprinted Kidney: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.78 3D Bioprinting Market for Bioprinted Kidney: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.79 3D Bioprinting Market for Bioprinted Kidney: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.80 3D Bioprinting Market for Bioprinted Liver: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.81 3D Bioprinting Market for Bioprinted Liver: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.82 3D Bioprinting Market for Bioprinted Liver: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.83 3D Bioprinting Market for Bioprinted Heart: Long-Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.84  3D Bioprinting Market for Bioprinted Heart: Long-Term (Till 2035), Base Scenario (USD Billion)
Table 15.85 3D Bioprinting Market for Bioprinted Heart: Long-Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.86 3D Bioprinting Market: Distribution by Region, 2018-2035, Conservative Scenario (USD Billion)
Table 15.87  3D Bioprinting Market: Distribution by Region, 2018, 2027 and 2035, (Base Scenario)
Table 15.88 3D Bioprinting Market: Distribution by Region, 2018, 2027 and 2035, (Optimistic Scenario) 
Table 15.89  3D Bioprinting Market: Distribution by Technology, 2018, 2027 and 2035, (Conservative Scenario)
Table 15.90  3D Bioprinting Market: Distribution by Technology, 2018, 2027 and 2035, Base Scenario 
Table 15.91 3D Bioprinting Market: Distribution by Technology, 2018, 2027 and 2035, Optimistic Scenario 
Table 15.92 3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 3D Bioprinting Solutions
  2. 3D Systems
  3. 3Dynamic Systems
  4. 500 Startups
  5. Accellta
  6. Advanced Solutions Life Sciences
  7. Aether
  8. Allevi (formerly BioBots)
  9. AMBER (Advanced Materials and BioEngineering Research)
  10. American Process
  11. Amgen
  12. Amuza
  13. AO Research Institute Davos (ARI)
  14. Aprecia Pharmaceuticals
  15. Aquitaine Science Transfert
  16. Arthritis Research UK
  17. Aspect Biosystems
  18. Autodesk
  19. AxolotlBio
  20. BASF
  21. Belgorod State University
  22. BellaSeno
  23. Ben Franklin Technology Partners
  24. Bio3D Technologies
  25. BioDan Group
  26. Bioink Solutions
  27. BioServe Space Technologies
  28. Bone Therapeutics
  29. Breakout Labs
  30. Brigham and Women's Hospital
  31. Cambridge University Hospitals
  32. Canada Foundation for Innovation (CFI)
  33. Cardiovascular Innovation Institute (CII)
  34. Carnegie Mellon University
  35. Celgene
  36. Cell Applications
  37. CELLINK
  38. Censo Biotechnologies (formerly Roslin Cellab)
  39. Center for Advancement of Science in Space (CASIS)
  40. Center for Gene and Cellular Therapies in the Treatment of Cancer (ONCOGEN)
  41. Chalmers University of Technology
  42. Children’s National Health System
  43. Chinese Academy of Engineering
  44. Chungnam National University Hospital
  45. Citizens Bank
  46. Clemson University
  47. Cold Springs Harbor Laboratory
  48. Collagen Solutions
  49. Columbia University
  50. Competence Centre TEDD (Tissue Engineering for Drug Development and Substance Testing)
  51. Cornell University
  52. Cosmo Bio
  53. CPA Group
  54. Crain’s Detroit Business
  55. Cyfuse Biomedical
  56. Danske Bank
  57. Dayton University 
  58. DBJ Capital
  59. DePuy Synthes Companies
  60. DiethelmKellerSiberHegner (DKSH)
  61. DigiLab
  62. Dreamit 
  63. Drexel University
  64. Eli Lilly
  65. Endure Capital
  66. EnvisionTEC
  67. EpiBone
  68. European Medicines Agency (EMA)
  69. Ewing Marion Kauffman Foundation
  70. FLENI
  71. Flexadyne
  72. Flipkart
  73. Foley & Lardner LLP
  74. Forschungsinstitut für Leder und Kunststoffbahnen (FILK)
  75. Founders Alliance
  76. Fraunhofer CMI
  77. Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine)
  78. French National Institute of Health and Medical Research (INSERM) 
  79. FUJIFILM Dimatix
  80. FundersClub
  81. GeSiM
  82. GoPrint3D
  83. Göteborg & Co
  84. Greiner Bio-One
  85. Hangzhou Electronic Science and Technology University
  86. Hannover Medical School
  87. Hanyang University
  88. Harvard Medical School
  89. Health Resources and Services Administration (HRSA)
  90. Heart Research Institute
  91. Helisys
  92. Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  93. Heriot-Watt University
  94. Hoffmann-La Roche
  95. Hogeschool Utrecht
  96. Hospital General Universitario Gregorio Marañón
  97. Houston Methodist
  98. Humane Society International
  99. I&L Biosystems
  100. Image Analysis Group (IAG)
  101. Indiana University
  102. Indiegogo
  103. Innovate UK
  104. InSCREENeX
  105. Institute for Drug Safety Sciences
  106. Institute of Burn Research, Southwest Hospital
  107. International Society for Biofabrication (IBSF)
  108. InvestX Capital
  109. Invetech
  110. INVITRO 
  111. IP Group
  112. IQ ARTISIA
  113. Izumi International
  114. JAFCO
  115. Johns Hopkins University
  116. Johnson & Johnson
  117. Korea Institute of Machinery and Materials (KIMM)
  118. Korean Institute of Science and Technology (KIST)
  119. Labsun
  120. Le Vivier
  121. Life Science Nord 
  122. L'Oréal
  123. Ludwig Maximilian University of Munich
  124. Luxexcel
  125. Maastricht University
  126. Made In Space
  127. MakerBot
  128. MaRS Innovation
  129. Mass Innovation Labs
  130. Massachusetts Institute of Technology (MIT)
  131. Mayo Clinic
  132. McGill University Health Centre
  133. Medical University of South Carolina (MUSC)
  134. Medicrea
  135. Medikine
  136. MedImmune
  137. MEDPRIN BIOTECH
  138. Med-Tech Innovation
  139. Merck 
  140. Merrill Corporation
  141. Metabridge
  142. Methuselah Foundation
  143. microdrop Technologies
  144. MicroFab Technologies
  145. MicroVentures
  146. Morriston Hospital
  147. Moss Enterprises
  148. Murdoch Childrens Research Institute (MCRI)
  149. My Doctor
  150. n3D Biosciences
  151. Nano Dimension
  152. Nanyang Technological University (NTU)
  153. National Aeronautics and Space Administration (NASA)
  154. National Cancer Institute (NCI)
  155. National Center for Advancing Translational Sciences (NCATS)
  156. National Eye Institute (NEI)
  157. National Institutes of Health (NIH)
  158. National Research Council-Industry Research Assistance Program (NRC-IRAP)
  159. National Science Foundation (NSF)
  160. National University of Singapore (NUS)
  161. Neatco
  162. NetScientific
  163. Neutec Group
  164. New Ventures BC
  165. Newcastle University
  166. NextGene Biosystem
  167. Nike
  168. Nippon Venture Capital
  169. North Carolina State University
  170. Northeastern University
  171. Northwestern University
  172. Novartis
  173. nScrypt
  174. Objet Geometries
  175. Ohio State University
  176. Oregon Health & Science University (OHSU)
  177. Organovo
  178. Ourobotics
  179. Oxford MEStar
  180. OxSyBio
  181. Pallasite Ventures
  182. Pandorum Technologies
  183. Pangaea Ventures
  184. Pennsylvania State University
  185. PeptiGelDesign Technologies
  186. Plum Alley Investments
  187. Poietis
  188. Praxis Pharmaceutical
  189. Precise Bio
  190. Pressure BioSciences
  191. Princeton University
  192. Qingdao Unique Products Develop
  193. Queensland University of Technology
  194. Rainbow Biosciences
  195. RBC Royal Bank
  196. REGEMAT 3D
  197. regenHU
  198. Regenovo Biotechnology
  199. Relentless Pursuit Partners
  200. Research Centre for Energy, Environment and Technology (CIEMAT)
  201. Rice University
  202. Ricoh
  203. Roche
  204. Rokit
  205. RoosterBio
  206. Roscosmos
  207. Royan Institute
  208. Sahlgrenska Academy
  209. Samsara Sciences
  210. Sanford Consortium for Regenerative Medicine
  211. Sanitas International
  212. SAP America
  213. SBH Sciences
  214. ScanSource
  215. Sciperio
  216. Scripps Clinic
  217. Seoul National University Bundang Hospital
  218. Seoul National University of Science and Technology
  219. Seraph Robotics
  220. Shanghai Man Heng Digital Technology
  221. Shapeways
  222. Shibuya Kogyo
  223. Shining3D
  224. Sichuan Revotek
  225. Siemens
  226. Sirris
  227. Skinprint
  228. Skolkovo Innovation Centre
  229. SME
  230. Solidscape
  231. Somos
  232. South by Southwest (SXSW) 
  233. Spanish National Research Council
  234. SPIRE Bioventures
  235. Stanford University
  236. Stem Cell Network
  237. Stemorgan Therapeutics
  238. SternAegis Ventures
  239. Stratasys
  240. Sunnybrook Health Sciences Centre
  241. SunP Biotech International
  242. Swansea University Medical School
  243. Symme 3D
  244. Tanner Friedman
  245. Technical University of Munich (TUM)
  246. TeViDo BioDevices
  247. The Finnish Funding Agency for Innovation
  248. The Scripps Research Institute
  249. The University of Virginia
  250. The Welsh Centre for Burns and Plastic Surgery
  251. The Welsh Centre for Printing and Coating
  252. ThermoFisher Scientific
  253. Tissue Engineering and Regenerative Medicine International Society
  254. Trideo
  255. Tsinghua University
  256. Tulane University
  257. UMC Utrecht
  258. UniQuest
  259. United Rocket and Space Corporation
  260. United States Food and Drug Administration
  261. Universidad Carlos III de Madrid
  262. University College of London
  263. University of Antwerp
  264. University of Bath
  265. University of Bordeaux
  266. University of British Columbia
  267. University of California
  268. University of Cambridge
  269. University of Colorado
  270. University of Eastern Finland
  271. University of Exeter
  272. University of Iowa College of Engineering
  273. University of Leuven
  274. University of Liverpool
  275. University of Louisville
  276. University of Manchester
  277. University of Manitoba
  278. University of Maryland
  279. University of Minnesota
  280. University of Missouri
  281. University of Nantes
  282. University of North Carolina
  283. University of Nottingham
  284. University of Otago
  285. University of Pennsylvania
  286. University of Pisa
  287. University of Sheffield
  288. University of South Australia 
  289. University of South Carolina
  290. University of Southampton
  291. University of Texas
  292. University of Tokyo
  293. University of Tokyo Edge Capital
  294. University of Toronto
  295. University of Victoria
  296. University of Washington
  297. University of Waterloo
  298. University of Wollongong
  299. University of Zurich
  300. Viscient Biosciences
  301. VisualPing
  302. Wake Forest Baptist Medical Center
  303. Wake Forest Institute for Regenerative Medicine
  304. Wallenberg Wood Science Center
  305. Watson Research Center
  306. WiSEED
  307. Wyss Institute (Harvard University)
  308. Xanofi
  309. Xilloc
  310. Yale University
  311. Z Corporation
  312. ZenBio
  313. Zurich University of Applied Sciences (ZHAW)

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com